{"prompt": "['Novartis', 'Confidential', 'Page 23', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'resolved on treatment. Based on the inability to identify discernable trends with QAW039', 'dose, regimen, time-of-onset, patient age and gender, concomitant medication, event type', 'and following detail ECG review, it was considered that these were most probably', 'coincidental events without a causal association to study drug. A formal QTc study has not', 'been completed for QAW039. Monitoring for changes in vital signs, ECGs and', 'biochemical parameters will be conducted.', 'Liver toxicity: Dose-dependent increases in liver weights with concomitant hepatocellular', 'hypertrophy were the primary findings during 2- and 13-week toxicity studies in mice.', 'These changes were considered to be a species-specific adaptive metabolic response with', 'no relevance for humans. Liver toxicity findings have not been identified in the healthy', 'volunteer and patient studies completed to date. Monitoring of liver function tests (LFTs)', 'will be conducted as described in Section 16.2 of this protocol.', 'Potential risk of idiosyncratic drug reactions CCN362 is an acylglucuronide metabolite of', 'QAW039 and its potential to covalently bind to plasma proteins, such as albumin, was', 'demonstrated in the human ADME (Absorption, distribution, metabolism, excretion)', 'study of QAW039 ([CQAW039A2104]) In the literature, in vivo binding of acyl', 'glucuronides to proteins has been reported to be associated with rare idiosyncratic drug', 'reactions (IDRs), although a causal connection of protein adduction to IDRs remains', 'uncertain (Regan et al 2010). There have been no IDRs observed with QAW039 treatment', 'in completed clinical trials. Surveillance of adverse events for identification of IDRs will', 'be conducted.', 'Drug-drug interactions: QAW039 and CCN362 did not show any relevant inhibition or', 'induction of the cytochrome P450 isoenzymes or inhibition of ubiquitous efflux', 'transporters. The most potent in-vitro inhibition by QAW039 was found for OATP1B1,', 'but clinically only a small impact was observed at 450 mg/day (~2-fold increase in Cmax', 'of simvastatin acid and rosuvastatin without change in AUC). Based on these data, as well', 'as recommendations in the simvastatin label, simvastatin doses of > 20 mg per day should', 'not be co-administered with QAW039; no relevant impact on the disposition of other co-', 'medications are expected with QAW039 dosed up to 450 mg/day. Patients on doses of', 'simvastatin > 20 mg, doses of atorvastatin > 40 mg, doses of pravastatin > 40mg, or doses', 'of pitavastatin > 2 mg per day (Elsby et al 2012, Deng et al 2008, No\u00e9 et al 2007, and', 'Kalliokoski and Niemi 2009), as well as patients on any statins with high CK levels (> 2 X', 'upper limit of normal (ULN)) at screening (Visit 1) will be excluded from the study.', 'Furthermore, patients on statin medication who are included in the study will have regular', 'monitoring for relevant symptoms and be subject to discontinuation based on persistent', 'myalgia and blood CK levels (Jacobson 2008).', 'Overall, the safety profile of QAW039 has been favorable across studies. Three Phase 2', 'studies in patients with asthma demonstrated the effect of QAW039 across the range of', 'asthma severities (mild to severe). For detailed information on the studies described', \"below, please refer to the Investigator's Brochure (IB).\"]['Novartis', 'Confidential', 'Page 24', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '5', 'Population', 'The study population will consist of approximately 93 male and female patients aged 18 and', 'above, diagnosed with nasal polyposis with polyps size > 4 (nasal polyp score, assessed by nasal', 'endoscopy) with a minimum score of 2 in each nostril; and a concomitant diagnosis of asthma.', '5.1', 'Inclusion criteria', 'Subjects eligible for inclusion in this study must meet all of the following criteria:', '1. Written informed consent must be obtained before any assessment is performed.', '2. Patients aged > 18 years with a diagnosis of nasal polyposis with polyp size score > 4 and', 'a minimum score of 2 in each nostril, measured by nasal endoscopy at screening and prior', 'to randomization on Run-in/Treatment Day 1 (to ensure no reduction in NPS following the', 'use of the mometasone furoate SoC therapy).', '3. Patients with a concomitant diagnosis of asthma for a period of at least 6 months prior to', 'screening.', '4. Have been on a stable asthma treatment regimen of at least inhaled corticosteroids (any', 'dose), alone for at least 6 months prior to Screening or ICS for 6 months prior to screening', 'with any other required, inhaled asthma medication (LABA, LAMA) added at least 6', 'weeks prior to Screening.', '5.2', 'Exclusion criteria', 'Subjects meeting any of the following criteria are not eligible for inclusion in this study.', '1. Asthma exacerbation, within 6 weeks prior to screening that required systemic', 'corticosteroids, hospitalization, or emergency room visit. When patients experience an', 'exacerbation between screening and the end of the 4-week Run-in period, and prior to', 'randomization, they will be considered screen failures and can be eligible for re-screening', 'only once the required 6 weeks post exacerbation window has passed.', '2. Chronic/maintenance use of oral corticosteroids (OCS) or systemic corticosteroids (SCS)', 'defined as any continuous use of OCS/SCS for a period of 1 month or more within 1 year', 'of Screening.', '3. Patients who, in the judgement of the Investigator, have a clinically significant ECG', 'abnormality such as, but not limited to, sustained ventricular tachycardia or clinically', 'significant second or third degree AV block without a pacemaker.', '4. Patients with a history of familial long QT syndrome or known family history of Torsades', 'de Pointes.', '5. Patients with a resting QTcF (Fridericia) > 450 msec (males) or > 460 msec (females) at', 'screening.', '6. Use of biologics (omalizumab, mepolizumab, reslisumab, dupilumab, benralizumab etc.,', 'for asthma or any other indications) that has potential to interfere/affect asthma or NP', 'disease progression, within 6 months of the start of the Run-in period.', '7. Use of medication for sino-nasal symptoms (antibiotics with or without OCS) within 30', 'days of Screening or during the Run-in period.']\n\n###\n\n", "completion": "END"}